Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Fused ring compound and use thereof
US9115136B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9115136-B2 |
| Application number | US-201314059868-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 22, 2013 |
| Priority date | Jan 30, 2009 |
| Publication date | Aug 25, 2015 |
| Grant date | Aug 25, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a novel compound represented by the following formula wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or metabolic diseases such as diabetes and the like, and the like.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound represented by the formula (I): wherein R 1 is a hydrogen atom, an optionally substituted C 1-6 alkyl, an optionally substituted 3- to 10-membered nonaromatic cyclic group or an optionally substituted 5- or 6-membered aromatic cyclic group, R 2 is an optionally substituted C 1-6 alkyl, R 3 is a hydrogen atom, a ha…
Assignees
Inventors
Classifications
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9115136B2 cover?
- Provided is a novel compound represented by the following formula wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hyperten…
- Who is the assignee on this patent?
- Takeda Pharmaceutical
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 25 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).